While systemic inhibition of TBK1 augments antitumor immunity in most cancer types tested, particularly with concomitant immune checkpoint blockade, detailed analyses of the role of TBK1 in immune, tumor, and tumor microenvironment/stromal cells will be necessary to determine the advisability of targeting TBK1 as an antineoplastic therapeutic approach. The gene discussed is TBK1; the disease is cancer.